JUST IN: Nigeria To Receive HIV Prevention Drug In March – NACA
NACA Announces Expected Rollout of Lenacapavir for HIV Prevention by March 2026
The National Agency for the Control of Aids (NACA) has confirmed that the rollout of Lenacapavir, a new option for HIV prevention, is anticipated to begin in Nigeria by March 2026. Toyin Aderibigbe, head of public relations for the agency, shared details in a recent statement outlining the agency’s preparations for the phased introduction of this injectable treatment.
NACA has completed readiness assessments across ten states, including Lagos, Kano, Benue, and the Federal Capital Territory, as part of the rollout preparation process. Lenacapavir offers a significant alternative to daily oral prevention drugs, requiring administration just twice a year.
The injectable pre-exposure prophylaxis (PrEP) is positioned as a critical component in Nigeria’s efforts to enhance HIV prevention and facilitate the control of the epidemic. It is expected to be accessible to individuals in Nigeria and 119 other low- and middle-income countries at a cost of $40 per person annually, facilitated by voluntary licensing agreements with generic manufacturers.
Regulatory approval has been granted by the National Agency for Food and Drug Administration and Control. Additionally, a national training program for healthcare providers has taken place in Abuja, followed by region-specific training sessions aimed at enhancing implementation in participating states.
To further support community engagement, NACA has developed various information, education, and communication materials as part of its comprehensive plan for the structured and quality-assured rollout of this new prevention measure.
